Grant: Collaborative Health Research Projects
École Polytechnique de Montréal
$56,652.00
Chitosan-siRNA nanoparticles for gene silencing in Atherosclerosis and Cancer
EF 2013-14
Résumé
A new class of drugs has been under development for the past decade, based on RNA interference, a mechanism of generegulation whose discovery was awarded the Nobel prize in 2006. The drugs are short sequences of RNA, the geneticmaterial that drives protein expression in all cells. It is possible to shut down the expression of pathological proteins usingthis mechanism by introducing RNA molecules into cells. Over the past decade the scientific and pharmaceutical communityhave recognised that the main limitation of making these drugs work is the lack of effective delivery systems. Our team hasbeen working in this area of RNA delivery for several years and have discovered and published new systems that can deliverRNA molecules to cells using a polymer of glucosamine called chitosan. We previously discovered and developed a productfor cartilage repair using this polymer and have now leveraged our ability to produce, modify and characterise thesepolymers to identify specific entities that are promising for RNA delivery. We have data in animal studies that suggest theymay be useful for treating Atherosclerosis. This project aims to produce specific compositions of chitosan and RNA that cantreat Atherosclerosis and Cancer based on silencing genes that are proven therapeutic targets. By the end of the project weexpect to identify new therapeutic approaches which could be used in people to treat these diseases.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
446418-2013
Name nom
Buschmann, Michael
Department département
Génie chimique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
56652
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Chitosan-siRNA nanoparticles for gene silencing in Atherosclerosis and Cancer
Keyword
NSERC
Application summary
A new class of drugs has been under development for the past decade, based on RNA interference, a mechanism of generegulation whose discovery was awarded the Nobel prize in 2006. The drugs are short sequences of RNA, the geneticmaterial that drives protein expression in all cells. It is possible to shut down the expression of pathological proteins usingthis mechanism by introducing RNA molecules into cells. Over the past decade the scientific and pharmaceutical communityhave recognised that the main limitation of making these drugs work is the lack of effective delivery systems. Our team hasbeen working in this area of RNA delivery for several years and have discovered and published new systems that can deliverRNA molecules to cells using a polymer of glucosamine called chitosan. We previously discovered and developed a productfor cartilage repair using this polymer and have now leveraged our ability to produce, modify and characterise thesepolymers to identify specific entities that are promising for RNA delivery. We have data in animal studies that suggest theymay be useful for treating Atherosclerosis. This project aims to produce specific compositions of chitosan and RNA that cantreat Atherosclerosis and Cancer based on silencing genes that are proven therapeutic targets. By the end of the project weexpect to identify new therapeutic approaches which could be used in people to treat these diseases.